DICOTnews June 2025
It is with great pleasure that I note the growing interest in Dicot Pharma and our recent development achievements. These, along with other updates, are summarized in this final edition of DICOT News before the summer holidays. Perhaps you're reading this in the hammock, on the balcony, by the water, or during your final days at work. Wherever you are, I wish you a wonderful summer.
Elin Trampe, CEO Dicot Pharma
Now 100% recruited
The Phase 2a study is nearing completion and we have just finalized participant recruitment. Thanks to this, we can now announce that the study will conclude in August, with results due no later than three months thereafter.
How does LIB-01 work?
Thanks to new research into the mechanism of action, we now know that LIB-01 affects the nerve and vascular structures that control erection. This makes our substance fundamentally different from existing treatments.
Best-in-class warrant redemption
The outcome of the TO 6 warrant exercise in April resulted in a subscription rate of 96% – achieved without underwriting – and a total capital raise of SEK 44 million. This put us at the top among small-cap pharmaceutical companies.
Q1 report in video format
Shortly after the end of March, we published this year’s first quarterly report. To make our reports more accessible, we now also produce an interview film in collaboration with Direkt Studios.
Record attendance at AGM
The Annual General Meeting held on May 6 was an energizing and positive event that brought together a large crowd – a clear reflection of our growing shareholder base, which has more than doubled over the past year. Thank you to everyone who attended!
Browse our flip-through version of the 2024 Annual Report here
Media attention
In June, the Netherlands' largest TV network RTL aired an interview with Elin in a segment on innovative Swedish companies. We’ve also recently been featured in The Pharma Navigator, the publication of the Confederation of Swedish Enterprise, Dagens Industri, the BioBiz Buzz podcast hosted by industry profile Mike Ward, and more.
Do you want to receive press releases the moment they are published?
If you want to read our press releases as soon as they’re released, click the link below and fill in just two fields.